SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing ...
Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven condition RAPT seeks to develop a differentiated anti-IgE therapy for ...
RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) has been assigned an average recommendation of “Hold” from the nine ratings firms that are currently covering the stock, MarketBeat reports. One ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results